Anti-Human CD2 [Clone G11] — Purified in vivo PLATINUM™ Functional Grade
Anti-Human CD2 [Clone G11] — Purified in vivo PLATINUM™ Functional Grade
Product No.: C965
Clone G11 Target CD2 Formats AvailableView All Product Type Monoclonal Antibody Isotype Mouse IgG2a Applications Costim , FC , IHC , in vivo , WB |
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Recommended Isotype Controls Recommended Isotype Controls Recommended Dilution Buffer Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2829885 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this G11 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application. WB Additional Applications Reported In Literature ? IHC Costim Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone G11 recognizes an epitope of human CD2. Background CD2 is a 45-59 kD type I transmembrane glycoprotein belonging to the Ig superfamily. CD2 is the receptor for LFA-3/CD58. CD2 serves as an adhesion receptor that binds to CD58; generating the activation of CD2-positive T cells and NK cells and in the regulation of their cytolytic activities. CD2 is a specific marker for T cells and NK cells. Hence, it can be used in immunohistochemistry to identify the occurrence of these cells in tissue sections. The vast majority of T cell lymphomas and leukemias express CD2 which makes it possible to distinguish these conditions from B-cell lymphomas. Antigen Distribution CD2 is present on normal peripheral blood lymphocytes, thymocytes, mature circulating T-cells and a subset of NK cells. Ligand/Receptor CD58 (LFA-3), CD48, CD59, CD15 PubMed NCBI Gene Bank ID UniProt.org Research Area Costimulatory Molecules . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Based on the available information, clone G11 has been developed and characterized for specific in vivo applications, though the search results primarily describe preclinical development rather than extensive in vivo mouse studies. Tumor Targeting ApplicationsThe G11 antibody, which is a human monoclonal antibody targeting domain C of tenascin-C, has been engineered specifically for tumor-targeting applications in vivo. Tenascin-C is overexpressed in various tumors, making it an attractive target for cancer therapy. The antibody demonstrates strong immunohistochemical staining of human tumor sections, indicating its potential utility for tumor targeting. Antibody Format EngineeringTo optimize in vivo performance, the G11 antibody has been cloned and expressed in multiple formats specifically designed for animal studies: Small Immunoprotein (SIP) Format: The scFv(G11) was fused with a human εCH4 domain to create a 75 kDa bivalent miniantibody. This format has proven superior to conventional IgG and scFv formats for radioimmunotherapeutic applications, as it provides improved pharmacokinetics and tumor penetration. Cytokine Fusion Proteins: The scFv(G11) was also fused with human interleukin-2 to create an immunocytokine fusion protein. Unlike similar constructs, the scFv(G11)-IL2 fusion proved to be exclusively monomeric under physiological conditions. CD2-Targeting ApplicationsA separate G11 clone targeting human CD2 has been developed as a functional grade preclinical antibody for in vivo use. This antibody is manufactured under animal-free conditions with extremely low endotoxin levels (<0.5 EU/mg) and high purity (>95%), making it suitable for in vivo mouse studies. The antibody is tested and guaranteed to be free of mouse pathogens that could compromise experimental results. Commonly used antibodies or proteins used in combination with G11 (an antibody targeting extra-domain C of tenascin-C) in the literature include:
Other antibody or protein strategies seen in the same field include:
In summary, the most commonly used antibodies or proteins with G11 in research are:
These combinations optimize tumor targeting, immune cell recruitment, and drug delivery for cancer therapeutics based on G11. The term "clone G11" appears in multiple contexts within scientific literature, most notably as an antibody clone targeting tenascin-C extra-domain C for tumor targeting, but also as unrelated clones (e.g., G11-6 for feline PD-L1, G11.2 for hybridoma sequencing, and others). The most significant and well-cited body of findings concerns the G11 antibody against tenascin-C, particularly in cancer research. Key findings for the G11 (tenascin-C) antibody clone:
Additional uses of similarly named clones ("G11") in literature:
Summary Table: Contexts of Notable ‘G11’ Clones in Literature
When citing "clone G11" in the context of cancer research and molecular imaging, findings overwhelmingly point to its value as a selective, high-affinity antibody for tumor targeting via tenascin-C. Other cited "G11" clones are clearly distinct and must not be conflated with the tumor-targeting antibody. The dosing regimens for clone G11, specifically in the context of tenascin-C antibodies, are not explicitly detailed in the provided search results. However, one relevant study mentions the use of iRGD fusion to ScFv G11 antibodies in U87-MG mice, which improved tumor targeting but does not specify dosing regimens for clone G11 itself. For other antibodies, dosing regimens typically depend on the specific target, application, and mouse model. For example, antibodies like anti-CTLA-4 (e.g., 9H10 and 9D9) are commonly used in cancer immunotherapy with doses ranging from 100 to 250 μg per mouse, administered intraperitoneally every 3 days. Similarly, anti-IL-4 (clone 11B11) is dosed at 1 mg per mouse every 4-5 days in tumor models. To determine the specific dosing regimen for clone G11 across different mouse models, it would be necessary to consult specific studies or literature related to the use of this clone in various experimental settings. References & Citations1. Stern, LJ. et al. (2005) Proc Natl Acad Sci U S A.102(10):3744-9 PubMed 2. Woetmann, Anders et al. (2010) Experimental Dermatology 19: 1096–1102. Article Link 3. Meuer, S.C. et al. (1984) Cell 36:897 4. Peterson, A. and Sneed, B. (1987) Nature 329:842 5. Bierer, B.E. et al. (1989) Annu. Rev Immunol. 7:579 6. Krensky, C.F. et al. (1982) Proc. Natl. Acad. Sci. USA 79:7489 7. Krensky, C.F. et al. (1983) J. Immunol. 131:611 Technical ProtocolsCertificate of Analysis |
Related Products
Prod No. | Description |
---|---|
S211 | |
R1364 | |
I-118 | |
M1188 | |
C247 | |
F1175 | |
S571 |
Formats Available
Prod No. | Description |
---|---|
C1839 | |
C109 | |
C111 | |
C110 | |
C1831 | |
C1833 | |
C1835 | |
C112 | |
C308 | |
C365 | |
C965 |
